Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

87.50 +1.10 (+1.27%)
Official Closing Price Updated: 4:10 PM EDT, Oct 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Discover which S&P500 stocks are making waves on Tuesday.
Curious about the top performers within the S&P500 index in the middle of the day on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Merck's Winrevair Cuts Clinical Worsening Risk By 76% Among Hypertension Patients
Merck reported Phase 3 results showing Winrevair significantly reduced clinical worsening in pulmonary arterial hypertension patients. 
Via Benzinga
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by... 
Via MarketMinute
IO Biotech Stock Plunges After FDA Recommends Another Trial For Investigational Cancer Vaccine
Via Stocktwits
Pharmaceutical Tariffs ‘A Light At The End Of The Trump Tunnel’ For Big Pharma, Says Jefferies
Via Stocktwits
Topics Government
Evaxion Stock Jumps A Whopping 43% Pre-Market – Here’s What Happened
Via Stocktwits
WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial
From Merck Sharp & Dohme
Via Business Wire
Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Program
The announcement from the group coincides with the deadline set by President Trump for 17 pharmaceutical companies to reduce drug prices in the U.S. to the levels paid by other developed countries. 
Via Stocktwits
Topics Government
Price Over Earnings Overview: Merck & Co
 
Via Benzinga
U.S. Government Teeters on Brink of Shutdown: Markets Brace for Uncertainty Amidst Data Blackout Fears
As the clock ticks towards the September 30, 2025, funding deadline, the United States federal government finds itself perilously close to another shutdown. Congressional leaders remain deadlocked on a... 
Via MarketMinute
Topics Bonds Economy Government
Johnson & Johnson's Hypothetical Rally: A Look at Potential 2025 Valuation Drivers
In a hypothetical scenario playing out just last week, leading up to September 27, 2025, Johnson & Johnson (NYSE: JNJ) experienced a significant stock rally, capturing the attention of investors and... 
Via MarketMinute
Topics Economy Intellectual Property
Healthcare Sector Reels: A Deep Dive into Thursday's -1.67% Plunge
The healthcare sector experienced a significant downturn on Thursday, September 25, 2025, shedding a notable -1.67% of its value and sending ripples of concern through the broader financial markets.... 
Via MarketMinute
Topics Economy
Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de 
Via Benzinga
Topics Government World Trade
Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now
BigBear.ai is bigger than both of these AI-focused companies now. That could change. 
Via The Motley Fool
Topics Artificial Intelligence
Robert F. Kennedy Jr. Faces Impeachment Push From Haley Stevens Over 'Health Care Chaos' And Rising Costs: 'Enough Is Enough'
Rep. Haley Stevens (D-Mich.) announced that she will introduce articles of impeachment against Health and Human Services Secretary Robert F. Kennedy Jr. 
Via Benzinga
Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America
Via Stocktwits
Topics Government
Moderna Stands By UK As Pharma Giants Criticize Pricing, UK Secures First Onshore mRNA Vaccine Production Centre
Moderna, Inc.‘s (NASDAQ: MRNA) UK chief Darius Hughes defended Britain's drug pricing policies after the country was branded the "worst in Europe." 
Via Benzinga
Peering Into Merck & Co's Recent Short Interest
Merck & Co's (NYSE: MRK) short interest as a percent of float has risen 16.98% since its last report. According to exchange reported data, there are now 27.71 million shares sold short, which is 1.24%... 
Via Benzinga
Merck & Co. Inc. (NYSE:MRK): A Prime Candidate for a Dependable Dividend Portfolio
Merck & Co. (MRK) offers a solid 3.97% dividend yield with a strong history of growth. Its reliable payout is backed by excellent profitability and a healthy balance sheet, making it a top choice for... 
Via Chartmill
United Kingdom The Worst European Country For Drug Prices: Eli Lilly CEO
Eli Lilly CEO Dave Ricks criticizes UK drug pricing and rebate rules as pharma giants scale back investments, warning of fewer new medicines. 
Via Benzinga
The Smartest Dividend Stock to Buy With $1,000 Right Now
Drug makers are out of favor right now, but the industry will survive. Here's one company that stands out as an investment option. 
Via The Motley Fool
Topics Intellectual Property
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead?
Pfizer has a huge yield right now, but it might make more sense for dividend investors to step down in yield to these two alternatives. 
Via The Motley Fool
Topics Intellectual Property
3 Dividend Stocks Perfect for Millennial Investors
All three of these names are not only built to last, they're being rebuilt to thrive for at least a few more decades. 
Via The Motley Fool
Topics Economy Intellectual Property Retirement
The Magnificent 7 Boom Just Triggered A Dot-Com Era Warning
The Magnificent Seven tech giants are now worth $21 trillion—8x more than top health care stocks, echoing dot-com bubble extremes. 
Via Benzinga
Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel'
President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current... 
Via Benzinga
Topics Government
Inflation's Lingering Shadow: Long-Term Expectations Rise Amidst Fed Rate Cuts
The financial markets are currently navigating a perplexing economic landscape where long-term inflation expectations are on the rise, even as the Federal Reserve initiates interest rate cuts. In... 
Via MarketMinute
Topics Bonds ETFs Economy
FDA Clears Merck's One-Minute Cancer Shot
FDA approves Merck's Keytruda Qlex injection for adults with solid tumors. Merck expects it to be available in the U.S. in September. 
Via Benzinga
Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might
The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Merck Snags A Key Approval Before Its Cash Cow Goes Off A Patent Cliff
But that doesn't mean Keytruda is safe from the looming patent cliff. 
Via Investor's Business Daily
Topics Intellectual Property
3 Dirt-Cheap Stocks to Buy Right Now
These stocks share several common denominators, including attractive valuations. 
Via The Motley Fool
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.